slides · global inventory
27 Cost Of Inaction
Loop collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 31,900
Current window 19,171-19,200
Pages 1,064
Rows per page 30
Loop
19,171-19,200 of 31,900
27
Includes details on milestone payments, royalties, and strategic support from Bayer.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
28
Includes a testimonial quote from a Bayer executive.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
29
Includes a data table comparing baseline PCT results with Ovaprene PCT results.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
30
The slide highlights the lack of existing FDA-approved therapies for FSAD.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
31
Uses a visual inequality symbol to emphasize the distinction between FSAD and HSDD.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
32
The slide uses a double-bordered box design to separate academic meta-analysis from commercial market research estimates.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
33
The slide uses a light blue callout box to group the product benefits and highlights the lack of current FDA-approved treatments for FSAD.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
34
The slide outlines the methodology and goals of a clinical trial, specifically mentioning the RESPOND study.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
35
The slide uses clinical trial data to justify the pivot to a topical delivery mechanism.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
36
Includes a table of pharmacokinetic parameters and a line chart showing plasma concentration over time.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
37
Study design is a small N=6 crossover trial.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
38
Dare Bioscience | Investor Presentation Deck | 54 slidesDare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
39
The slide uses a side-by-side comparison layout to contrast the biological route with the technical solution.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
40
The slide frames the market opportunity and clinical need for a non-oral hormone therapy.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
41
The slide highlights statistically significant improvements (p<0.01) across multiple clinical endpoints.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
42
The slide details the specific regulatory strategy for a pharmaceutical product, focusing on the 505(b)(2) pathway.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
43
Dare Bioscience | Investor Presentation Deck | 54 slidesDare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
44
The slide uses a grid-based layout to organize product candidates by development stage (Phase 1 vs Preclinical).Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
45
The slide highlights the clinical need for non-daily dosing progesterone delivery systems.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
46
The slide highlights a specific clinical need for breast cancer survivors.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
47
Includes clinical trial data and comparative pharmacokinetic data against oral tamoxifen.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
48
Text-dense clinical study summary slide with a red banner headline and subtitle; reports specific quantitative outcomes (e.g. p=0.04, 36 days, 17 women, dose levels 1-20 mg).Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
49
Includes regulatory disclaimer and multiple source citations.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
50
The slide uses a comparative framework to highlight the competitive advantage of the proposed product over the incumbent Depo-Provera.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
51
The slide outlines development phases from 2021 through 2026, including specific grant amounts.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
52
The slide uses a callout box to highlight the mechanism and benefits of GML.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
53
The slide highlights the clinical need for vaginal health solutions and the specific technical challenge of maintaining microbe viability in low-resource settings.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
54
The slide uses a play on the company name 'Dare' to create a brand slogan.Dare Bioscience | Investor Presentation Deck | 54 slides · Daré Bioscience
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
08
The slide uses a stacked bar chart to visualize the composition of the $5.5B savings target.Disney | Results Presentation Deck | 30 slides · Disney
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
09
The slide uses a horizontal process arrow diagram to represent the strategic pillars.Disney | Results Presentation Deck | 30 slides · Disney
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit